Share this article on:

A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

Clumeck, Nathan MD*; Molina, Jean-Michel MD; Henry, Keith MD; Gathe, Joseph MD§; Rockstroh, Jürgen K. MD; DeJesus, Edwin MD; Wei, Xuelian PhD#; White, Kirsten PhD#; Fordyce, Marshall W. MD#; Rhee, Martin S. MD#; Szwarcberg, Javier MD#

JAIDS Journal of Acquired Immune Deficiency Syndromes: March 1st, 2014 - Volume 65 - Issue 3 - p e121–e124
doi: 10.1097/QAI.0000000000000089
Letters to the Editor

Supplemental Digital Content is Available in the Text.

*Maladies Infectieuses, Brussels, Belgium

Service de Maladies Infectieuses et Tropicales, Hospital Saint-Louis, AP-HP and University of Paris Sorbonne Cité, INSERM, Paris, France

Department of Infectious Diseases, Hennepin County Medical Center, Minneapolis, MN

§Therapeutic Concepts, Houston, TX

Department of Medicine I, University of Bonn, Bonn, Germany

Orlando Immunology Center, Orlando, FL

#Gilead Sciences, Foster City, CA

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

Presented at the 11th International Congress on Drug Therapy in HIV Infection, November 11–15, 2012, Glasgow, United Kingdom.

N.C., J.-M.M., K.H., J.G., J.R., and E.D.J. are all principal investigators and enrolled at least 5 participants in this study. All authors have reviewed the results of this study and manuscript.

N.C. has received lecture fees and advisory board honoraria from Gilead, Merck, Tibotec Janssen, and ViiV Healthcare. J.-M.M. has acted as a consultant, participated in advisory boards, has received speaker fees, and has been an investigator for clinical trials for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Merck, Tibotec, and ViiV Healthcare. J.K.R. has received lecture fees and advisory board honoraria from Abbott, Bristol-Myers Squibb, Gilead Sciences, Boehringer Ingelheim, GlaxoSmithKline, ViiV, Tibotec, Janssen, Merck, and Pfizer. X.W., K.W., M.F., M.S.R., and J.S. are employees of the Sponsor of this study, Gilead Sciences, and were the scientific, medical, and operational leaders responsible for this study's design, conduct, oversight, and analyses.

K.H. has received research grant support from Gilead Sciences, GlaxoSmithKline, US Centers for Disease Control, and the US National Institutes of Health and consulting fees as an advisory board member for Gilead Sciences. E.D.J. has received research grant support from Abbott Laboratories, Achillion Pharmaceuticals, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffmann LaRoche, Idenix, Janssen, Merck, Pfizer, Sangamo, Taimed, Tobira, and Vertex and consulting fees as a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Vertex. J.G. has received research grant support from Abbott Laboratories, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, and Janssen and receives consulting fees from Abbott Laboratories and Boehringer Ingelheim.

© 2014 by Lippincott Williams & Wilkins